ID   DHPH_PAENI              Reviewed;         397 AA.
AC   Q93NG3;
DT   03-SEP-2014, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   05-DEC-2018, entry version 94.
DE   RecName: Full=2,6-dihydroxypyridine 3-monooxygenase;
DE            Short=2,6-DHPH;
DE            EC=1.14.13.10;
GN   Name=dhpH;
OS   Paenarthrobacter nicotinovorans (Arthrobacter nicotinovorans).
OG   Plasmid pAO1.
OC   Bacteria; Actinobacteria; Micrococcales; Micrococcaceae;
OC   Paenarthrobacter.
OX   NCBI_TaxID=29320;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY,
RP   COFACTOR, SUBUNIT, BIOPHYSICOCHEMICAL PROPERTIES, AND PATHWAY.
RC   STRAIN=ATCC 49919 / DSM 420 / JCM 3874 / NBRC 15511; PLASMID=pAO1;
RX   PubMed=11514508; DOI=10.1128/JB.183.18.5262-5267.2001;
RA   Baitsch D., Sandu C., Brandsch R., Igloi G.L.;
RT   "Gene cluster on pAO1 of Arthrobacter nicotinovorans involved in
RT   degradation of the plant alkaloid nicotine: cloning, purification, and
RT   characterization of 2,6-dihydroxypyridine 3-hydroxylase.";
RL   J. Bacteriol. 183:5262-5267(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 49919 / DSM 420 / JCM 3874 / NBRC 15511; PLASMID=pAO1;
RX   PubMed=12618462; DOI=10.1128/JB.185.6.1976-1986.2003;
RA   Igloi G.L., Brandsch R.;
RT   "Sequence of the 165-kilobase catabolic plasmid pAO1 from Arthrobacter
RT   nicotinovorans and identification of a pAO1-dependent nicotine uptake
RT   system.";
RL   J. Bacteriol. 185:1976-1986(2003).
RN   [3]
RP   IDENTIFICATION.
RX   PubMed=24826896; DOI=10.1371/journal.pone.0097250;
RA   Shearer A.G., Altman T., Rhee C.D.;
RT   "Finding sequences for over 270 orphan enzymes.";
RL   PLoS ONE 9:E97250-E97250(2014).
RN   [4]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) IN COMPLEX WITH FAD, AND
RP   MUTAGENESIS OF CYS-323.
RX   PubMed=18440023; DOI=10.1016/j.jmb.2008.03.032;
RA   Treiber N., Schulz G.E.;
RT   "Structure of 2,6-dihydroxypyridine 3-hydroxylase from a nicotine-
RT   degrading pathway.";
RL   J. Mol. Biol. 379:94-104(2008).
CC   -!- FUNCTION: Catalyzes the conversion of 2,6-dihydroxypyridine into
CC       2,3,6-trihydroxypyridine in the nicotine degradation pathway.
CC       {ECO:0000269|PubMed:11514508}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2,6-dihydroxypyridine + H(+) + NADH + O2 = 2,3,6-
CC         trihydroxypyridine + H2O + NAD(+); Xref=Rhea:RHEA:16917,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16683, ChEBI:CHEBI:17681, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57945; EC=1.14.13.10;
CC         Evidence={ECO:0000269|PubMed:11514508};
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:11514508};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.0000083 M for 2,6-dihydroxypyridine
CC         {ECO:0000269|PubMed:11514508};
CC       pH dependence:
CC         Optimum pH is 8.0. {ECO:0000269|PubMed:11514508};
CC       Temperature dependence:
CC         Optimum temperature is 20 degrees Celsius.
CC         {ECO:0000269|PubMed:11514508};
CC   -!- PATHWAY: Alkaloid degradation; nicotine degradation.
CC       {ECO:0000269|PubMed:11514508}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:11514508,
CC       ECO:0000269|PubMed:18440023}.
DR   EMBL; AF373840; AAK64255.1; -; Genomic_DNA.
DR   EMBL; AJ507836; CAD47937.1; -; Genomic_DNA.
DR   RefSeq; WP_016359448.1; NC_021229.1.
DR   RefSeq; YP_007988763.1; NC_021229.1.
DR   PDB; 2VOU; X-ray; 2.60 A; A/B/C=1-397.
DR   PDBsum; 2VOU; -.
DR   ProteinModelPortal; Q93NG3; -.
DR   SMR; Q93NG3; -.
DR   GeneID; 15879626; -.
DR   KEGG; ag:AAK64255; -.
DR   KO; K19189; -.
DR   BioCyc; MetaCyc:MONOMER-1001; -.
DR   BRENDA; 1.14.13.10; 449.
DR   SABIO-RK; Q93NG3; -.
DR   UniPathway; UPA00106; -.
DR   EvolutionaryTrace; Q93NG3; -.
DR   GO; GO:0018663; F:2,6-dihydroxypyridine 3-monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019608; P:nicotine catabolic process; IDA:UniProtKB.
DR   Gene3D; 3.50.50.60; -; 1.
DR   InterPro; IPR002938; FAD-bd.
DR   InterPro; IPR036188; FAD/NAD-bd_sf.
DR   Pfam; PF01494; FAD_binding_3; 1.
DR   SUPFAM; SSF51905; SSF51905; 1.
PE   1: Evidence at protein level;
KW   3D-structure; FAD; Flavoprotein; NAD; Nucleotide-binding;
KW   Oxidoreductase; Plasmid.
FT   CHAIN         1    397       2,6-dihydroxypyridine 3-monooxygenase.
FT                                /FTId=PRO_0000430255.
FT   NP_BIND      14     16       FAD. {ECO:0000269|PubMed:18440023}.
FT   NP_BIND      35     36       FAD. {ECO:0000269|PubMed:18440023}.
FT   NP_BIND     316    320       FAD. {ECO:0000269|PubMed:18440023}.
FT   BINDING      49     49       FAD; via amide nitrogen and carbonyl
FT                                oxygen. {ECO:0000269|PubMed:18440023}.
FT   BINDING     120    120       FAD; via amide nitrogen and carbonyl
FT                                oxygen. {ECO:0000269|PubMed:18440023}.
FT   BINDING     306    306       FAD. {ECO:0000269|PubMed:18440023}.
FT   MUTAGEN     323    323       C->S: Does not cause structural
FT                                disturbance.
FT                                {ECO:0000269|PubMed:18440023}.
FT   STRAND        6     11       {ECO:0000244|PDB:2VOU}.
FT   HELIX        15     26       {ECO:0000244|PDB:2VOU}.
FT   STRAND       30     34       {ECO:0000244|PDB:2VOU}.
FT   STRAND       36     40       {ECO:0000244|PDB:2VOU}.
FT   STRAND       47     49       {ECO:0000244|PDB:2VOU}.
FT   HELIX        52     60       {ECO:0000244|PDB:2VOU}.
FT   HELIX        65     67       {ECO:0000244|PDB:2VOU}.
FT   STRAND       74     79       {ECO:0000244|PDB:2VOU}.
FT   TURN         80     82       {ECO:0000244|PDB:2VOU}.
FT   STRAND       85     90       {ECO:0000244|PDB:2VOU}.
FT   STRAND       95     97       {ECO:0000244|PDB:2VOU}.
FT   HELIX        98    109       {ECO:0000244|PDB:2VOU}.
FT   STRAND      120    125       {ECO:0000244|PDB:2VOU}.
FT   STRAND      130    134       {ECO:0000244|PDB:2VOU}.
FT   STRAND      139    147       {ECO:0000244|PDB:2VOU}.
FT   HELIX       154    160       {ECO:0000244|PDB:2VOU}.
FT   STRAND      165    176       {ECO:0000244|PDB:2VOU}.
FT   HELIX       183    189       {ECO:0000244|PDB:2VOU}.
FT   STRAND      192    198       {ECO:0000244|PDB:2VOU}.
FT   STRAND      201    208       {ECO:0000244|PDB:2VOU}.
FT   STRAND      218    226       {ECO:0000244|PDB:2VOU}.
FT   HELIX       231    236       {ECO:0000244|PDB:2VOU}.
FT   STRAND      246    249       {ECO:0000244|PDB:2VOU}.
FT   HELIX       251    253       {ECO:0000244|PDB:2VOU}.
FT   HELIX       256    266       {ECO:0000244|PDB:2VOU}.
FT   HELIX       271    279       {ECO:0000244|PDB:2VOU}.
FT   STRAND      284    291       {ECO:0000244|PDB:2VOU}.
FT   STRAND      296    298       {ECO:0000244|PDB:2VOU}.
FT   STRAND      301    303       {ECO:0000244|PDB:2VOU}.
FT   HELIX       305    307       {ECO:0000244|PDB:2VOU}.
FT   HELIX       313    315       {ECO:0000244|PDB:2VOU}.
FT   HELIX       318    335       {ECO:0000244|PDB:2VOU}.
FT   HELIX       339    368       {ECO:0000244|PDB:2VOU}.
FT   TURN        369    371       {ECO:0000244|PDB:2VOU}.
FT   HELIX       379    381       {ECO:0000244|PDB:2VOU}.
FT   STRAND      382    384       {ECO:0000244|PDB:2VOU}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000244; PDB:2VOU; INT; 10-SEP-2014.
**EV ECO:0000269; PubMed:11514508; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:18440023; XXX; 01-JAN-1900.
**ZA SYP, 25-JUN-2014;
SQ   SEQUENCE   397 AA;  43400 MW;  D257CDC11D516CBE CRC64;
     MSPTTDRIAV VGGSISGLTA ALMLRDAGVD VDVYERSPQP LSGFGTGIVV QPELVHYLLE
     QGVELDSISV PSSSMEYVDA LTGERVGSVP ADWRFTSYDS IYGGLYELFG PERYHTSKCL
     VGLSQDSETV QMRFSDGTKA EANWVIGADG GASVVRKRLL GIEPTYAGYV TWRGVLQPGE
     VADDVWNYFN DKFTYGLLDD GHLIAYPIPG RENAESPRLN FQWYWNVAEG PDLDELMTDV
     RGIRLPTSVH NNSLNPHNLR QFHSKGESLF KPFRDLVLNA SSPFVTVVAD ATVDRMVHGR
     VLLIGDAAVT PRPHAAAGGA KACDDARTLA EVFTKNHDLR GSLQSWETRQ LQQGHAYLNK
     VKKMASRLQH GGSFEPGNPA FAFGLPKVDE PSVVTNS
//
